Jackson T Wright

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8405706/publications.pdf

Version: 2024-02-01

67 papers	15,531 citations	147801 31 h-index	118850 62 g-index
68 all docs	68 docs citations	68 times ranked	16603 citing authors

#	Article	IF	Citations
1	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2015, 373, 2103-2116.	27.0	4,880
2	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018, 71, e13-e115.	2.7	3,332
3	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 288, 2421.	7.4	1,792
4	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged â‰¥75 Years. JAMA - Journal of the American Medical Association, 2016, 315, 2673.	7.4	991
5	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 553.	7.4	786
6	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials, 2014, 11, 532-546.	1.6	408
7	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	6.1	364
8	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA - Journal of the American Medical Association, 2019, 322, 524.	7.4	285
9	Potential U.S. Population Impact ofÂtheÂ2017 ACC/AHA High Blood PressureÂGuideline. Journal of the American College of Cardiology, 2018, 71, 109-118.	2.8	283
10	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiology, 2017, 2, 635.	6.1	251
11	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2021, 384, 1921-1930.	27.0	214
12	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71, 848-857.	2.7	190
13	Sex-Related Disparities in CKD Progression. Journal of the American Society of Nephrology: JASN, 2019, 30, 137-146.	6.1	157
14	Successful Blood Pressure Control in the African American Study of Kidney Disease and Hypertension. Archives of Internal Medicine, 2002, 162, 1636.	3.8	122
15	Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis. Hypertension, 2015, 65, 93-100.	2.7	122
16	Blood Pressure Assessment in AdultsÂinÂClinicalÂPractice and Clinic-Based Research. Journal of the American College of Cardiology, 2019, 73, 317-335.	2.8	114
17	Determinants of Salt Sensitivity in Black and White Normotensive and Hypertensive Women. Hypertension, 2003, 42, 1087-1092.	2.7	97
18	SPRINT Trial Results. Hypertension, 2016, 67, 263-265.	2.7	79

#	Article	IF	Citations
19	The Role of the Cytochrome P450-Dependent Metabolites of Arachidonic Acid in Blood Pressure Regulation and Renal Function A Review. American Journal of Hypertension, 1997, 10, 356-365.	2.0	76
20	Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults. Hypertension, 2018, 72, 1365-1373.	2.7	75
21	Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney International, 2015, 87, 169-175.	5.2	71
22	BP Control and Long-Term Risk of ESRD and Mortality. Journal of the American Society of Nephrology: JASN, 2017, 28, 671-677.	6.1	71
23	Intensive vs Standard Blood Pressure Control in Adults 80â€‰Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. Journal of the American Geriatrics Society, 2020, 68, 496-504.	2.6	59
24	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. Hypertension, 2020, 75, 660-667.	2.7	57
25	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
26	Guideline-Driven Management of Hypertension. Circulation Research, 2021, 128, 827-846.	4.5	52
27	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	3.9	47
28	Estimating Time to ESRD Using Kidney Failure Risk Equations: Results From the African American Study of Kidney Disease and Hypertension (AASK). American Journal of Kidney Diseases, 2015, 65, 394-402.	1.9	45
29	Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 60-68.	4.5	38
30	Rationale for Ambulatory and Home Blood Pressure Monitoring Thresholds in the 2017 American College of Cardiology/American Heart Association Guideline. Hypertension, 2019, 73, 33-38.	2.7	38
31	Reducing Health Inequities in the U.S.. Journal of the American College of Cardiology, 2016, 68, 517-524.	2.8	36
32	Sex Differences in the Incidence of Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S86-93.	2.2	30
33	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. JAMA Neurology, 2022, 79, 380.	9.0	26
34	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. American Journal of Hypertension, 2018, 31, 97-107.	2.0	25
35	Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. Clinical Pharmacology and Therapeutics, 1993, 53, 479-484.	4.7	23
36	Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study. American Journal of Kidney Diseases, 2021, 78, 200-209.e1.	1.9	23

#	Article	IF	Citations
37	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney International, 2016, 90, 1348-1356.	5.2	22
38	Lowering Blood Pressure With Î²â€Blockers in Combination With Other Reninâ€Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. Journal of Clinical Hypertension, 2007, 9, 842-849.	2.0	18
39	The effects of weight change on glomerular filtration rate. Nephrology Dialysis Transplantation, 2015, 30, 1870-1877.	0.7	18
40	Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. Nephrology Dialysis Transplantation, 2020, 35, 1377-1384.	0.7	16
41	Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. Journal of the American Society of Hypertension, 2015, 9, 670-679.	2.3	14
42	Recognition and Management of Hypertension in Older Persons: Focus on African Americans. Journal of the American Geriatrics Society, 2015, 63, 2130-2138.	2.6	13
43	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure. Hypertension, 2021, 77, 813-822.	2.7	13
44	Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. American Journal of Hypertension, 2004, 17, 734-742.	2.0	12
45	A 59-Year-Old Man With "Racial Characteristics". Journal of Clinical Hypertension, 2007, 9, 128-133.	2.0	10
46	The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. American Journal of Hypertension, 2018, 31, 609-614.	2.0	9
47	Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. JAMA Network Open, 2020, 3, e2025127.	5.9	9
48	SPRINT Revisited: Updated Results and Implications. Hypertension, 2021, 78, 1701-1710.	2.7	9
49	Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 830-832.	2.3	6
50	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. BMC Nephrology, 2021, 22, 69.	1.8	6
51	Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension, 2022, 79, 338-348.	2.7	6
52	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes, Obesity and Metabolism, 2018, 20, 629-637.	4.4	5
53	Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients. Circulation Research, 2018, 123, 531-534.	4.5	4
54	Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association, 2017, 109, 172-181.	0.8	3

#	Article	IF	Citations
55	Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering) Tj ETQq1 1 0.784314 rgBT /Ove	2.0	3
56	Realâ€World Evidence Supports Optimally Dosed Thiazideâ€Type Diuretics As Preferred in Treatment Regimens of Older Adults with Hypertension. Journal of the American Geriatrics Society, 2015, 63, 1045-1047.	2.6	2
57	The Associations between Peripheral Artery Disease and Physical Outcome Measures in Men and Women with Chronic Kidney Disease. Annals of Vascular Surgery, 2016, 35, 111-120.	0.9	2
58	Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. Journal of the National Medical Association, 2018, 110, 343-351.	0.8	2
59	First-Year Anniversary of the 2017 Hypertension Guideline. Circulation, 2018, 138, 1774-1776.	1.6	1
60	The Targeted Management (TEAM) Intervention for Reducing Stroke Risk in African American Men: Rationale and Study Design of a Prospective Randomized Controlled Trial. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 513-522.	2.7	1
61	Policies to solve the salt problem. Preventive Medicine, 2021, 145, 106448.	3.4	1
62	Abstract W P172: Baseline Quality of Life and Risk of Stroke in the Antihypertensive and Lipid Lowering to Prevent Heart Attack (ALLHAT) Trial. Stroke, 2015, 46, .	2.0	1
63	Angiotensin-Converting Enzyme Inhibitors and Diuretics: Optimal Combination Therapy. Annals of Internal Medicine, 2004, 141, 893.	3.9	0
64	Module 3: Using thiazide-type diuretics in African Americans with hypertension. Journal of Family Practice, 2012, 61, S20-2; quiz S31.	0.2	0
65	MO094: Intensive Blood Pressure Lowering and Myocardial Fibrosis Biomarkers in Individuals With and Without CKD: Results From the Systolic Blood Pressure Intervention Trial (Sprint). Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
66	Blood Pressure Control in Hispanic Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. Circulation, 2001, 103, 1348-1348.	1.6	0
67	Abstract 047: Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trials (SPRINT): A Randomized Control Trial. Hypertension, 2017, 70, .	2.7	0